London, UK: 3 October, 2006 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces that three Non-Executive Directors of Antisoma have taken part of their fees for the quarter ended 30 September 2006 in shares pursuant to resolutions of the Board of Directors dated 14 September 2004 and subsequently.
The newly issued shares were issued at a price of 22.5p per share, being the mid-market closing price on the last trading day of the quarter (29 September 2006). The relevant Directors have agreed not to dispose of the shares allotted to them for a minimum period of one year.
The allotment and total holdings following these allotments are shown below.
Director Allotted Total Percentage of 2 October 2006 holding issued ordinary shares
Grahame Cook 16,111 1,186,155 0.32% Michael Pappas 12,500 589,071 0.16% Dale Boden 12,916 700,278* 0.19%
* Mr Boden's total holding includes a beneficial interest totalling 638,469 ordinary Antisoma shares held by BF Capital, BFC III Ltd and by The Sentinel I Trust.
Application will be made to the London Stock Exchange and the UK Listing Authority for the admission of the 41,527 new ordinary shares of 1p each. The total number of ordinary shares in the Company in issue and admitted to the Official List following the above allotments will be 370,887,905.
The shares when issued will rank pari passu with the company's existing ordinary shares.
Enquiries: Raymond Spencer, CFO +44 (0)208 799 8200 Antisoma plc
Background on Antisoma Based in London, UK, Antisoma is a biopharmaceutical company that develops novel products for the treatment of cancer. Antisoma fills its development pipeline by acquiring promising new product candidates from internationally recognised academic or cancer research institutions. Its core activity is the preclinical and clinical development of these drug candidates. Please visit www.antisoma.co.uk for further information about Antisoma.
---END OF MESSAGE---
